Advertisement

Watertown drug-delivery company pSivida Corp. is expanding beyond eye treatments into orthopedics with an evaluation agreement with Hospital for Special Surgery in New York.

Company president and CEO Paul Ashton also said the company expects the U.S. Food and Drug Administration (FDA) to rule on its Iluvien treatment for diabetic macular edema, the leading cause of blindness in diabetics under age 65, by Nov. 12. The company’s partner, Alimera Sciences Inc., resubmitted a new drug application in May.

SOURCE

Advertisement
Advertisement